Slika omota

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease

Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9). The function of PCSK9 is to bind receptors for LDL...

Spremljeno u:

Bibliografski detalji
Glavni autori:	Natalia Pauli (Autor), Monika Rac (Autor)
Format:	Knjiga
Izdano:	Polish Pharmaceutical Society, 2020-07-01T00:00:00Z.
Teme:	article
Online pristup:	Connect to this object online.
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
od: Constantine E Kosmas, i dr.
Izdano: (2017)

Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium
od: Tahir Mahmood, i dr.
Izdano: (2020)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
od: Moiud Mohyeldin
Izdano: (2024)

The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
od: Natalia Ilnicka, i dr.
Izdano: (2023)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
od: A. V. Blokhina, i dr.
Izdano: (2022)

Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries
od: Furio Colivicchi, i dr.
Izdano: (2020)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
od: Martin Jozef Péč, i dr.
Izdano: (2023)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
od: Chen CC, i dr.
Izdano: (2018)

THE PROBLEM OF THE OPTIMAL PHARMACOTHERAPY CHOICE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
od: S. R. Gilyarevskiy, i dr.
Izdano: (2015)

THE PROBLEM OF THE OPTIMAL PHARMACOTHERAPY CHOICE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
od: S. R. Gilyarevskiy, i dr.
Izdano: (2015)

The impact of lipid-lowering medications on coronary artery plaque characteristics
od: Vishnu Priya Pulipati, i dr.
Izdano: (2021)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
od: Vittoria Cammisotto, i dr.
Izdano: (2022)

Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study
od: Zhao X, i dr.
Izdano: (2023)

Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review
od: Nikolaos Velidakis, i dr.
Izdano: (2024)

A Comprehensive Review of PCSK9 Inhibitors
od: Caroline Coppinger BS, i dr.
Izdano: (2022)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
od: Lin Zhou, i dr.
Izdano: (2024)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
od: A. A. Nekipelova, i dr.
Izdano: (2023)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
od: Saeideh Sobati, i dr.
Izdano: (2020)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
od: article Editorial
Izdano: (2023)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
od: Yu. A. Karpov
Izdano: (2019)

Pharmacotherapy efficacy and safety criteria based on spectral shifts in elder patients with arterial hypertension and coronary artery disease
od: V. A. Shtanko, i dr.
Izdano: (2017)

Pharmacotherapy efficacy and safety criteria based on spectral shifts in elder patients with arterial hypertension and coronary artery disease
od: V. A. Shtanko, i dr.
Izdano: (2017)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
od: Kosmas CE, i dr.
Izdano: (2020)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
od: S. Yu. Volkova, i dr.
Izdano: (2023)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
od: K. O. Shnaider, i dr.
Izdano: (2023)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
od: K Gadkar, i dr.
Izdano: (2014)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
od: Tsuyoshi Yamamoto, i dr.
Izdano: (2012)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
od: Maya Safarova, i dr.
Izdano: (2024)

Sex difference in circulating PCSK9 and its clinical implications
od: Fang Jia, i dr.
Izdano: (2022)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
od: Alessia Silla, i dr.
Izdano: (2023)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
od: Mohsin Haseeb, i dr.
Izdano: (2023)

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
od: Seyyed Majid Eslami, i dr.
Izdano: (2017)

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
od: Łukasz Wołowiec, i dr.
Izdano: (2023)

Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease
od: S. K. Zyryanov, i dr.
Izdano: (2021)

Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease
od: Yuanyuan Xu, i dr.
Izdano: (2017)

Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation
od: Diana N. Vikulova, i dr.
Izdano: (2020)

Di-(2-ethylhexyl) Phthalate Limits the Lipid-Lowering Effects of Simvastatin by Promoting Protein Degradation of Low-Density Lipoprotein Receptor: Role of PPARγ-PCSK9 and LXRα-IDOL Signaling Pathways
od: Bei-Chia Guo, i dr.
Izdano: (2023)

Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort
od: Bruce A. Warden, i dr.
Izdano: (2020)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
od: Hye Duck Choi, i dr.
Izdano: (2023)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
od: Paul C Langley, Dr
Izdano: (2017)